Posting of Annual Report and Notice of AGM

RNS Number : 8209E

Aptamer Group PLC

01 November 2022

 

1 November 2022

Aptamer Group plc

("Aptamer", the "Company" or the "Group")

Posting of Annual Report and Accounts and Notice of Annual General Meeting

Aptamer Group plc (AIM: APTA), the developer of novel Optimer^® binders to enable innovation in the life sciences industry, today announces that the Annual Report and Accounts for the year ended 30 June 2022 and Notice of its 2022 Annual General Meeting (AGM) were posted to shareholders today. These documents are available on the Company's website at https://aptamergroup.com/ .

Aptamer will host its AGM at 13:30 GMT on 01 December 2022 at the offices of Liberum at Level 12 Ropemaker Place, 25 Ropemaker Street, London, EC2Y 9LY. The AGM will be held in person only and there will be no new information presented at the meeting.

The results of voting on all resolutions at the AGM will be announced to the London Stock Exchange and the full results of the voting published on the Company's website, as soon as practicable after the conclusion of the AGM.

- ENDS -

For further information, please contact:

Aptamer Group plc

Dr Arron Tolley    [phone]

SPARK Advisory Partners Limited - Nominated Adviser  

Andrew Emmott / Adam Dawes  [phone]

Liberum Capital Limited - Broker

Richard Lindley / Ben Cryer / Will Hall / Cara Murphy   [phone]

Consilium Strategic Communications

Matthew Neal / Chris Welsh / Lucy Featherstone       [phone]

[e-mail]

About Aptamer Group plc

Aptamer Group develops custom affinity binders through its proprietary Optimer® platform to enable new approaches in therapeutics, diagnostics and research applications. The Company strives to deliver transformational solutions that meet the needs of life science researchers and developers through the use of its proprietary Optimer platform.

Optimer binders are oligonucleotide affinity ligands that can function as an antibody alternative. The global antibody market is currently worth over $145.0 billion. Optimer binders are engineered to address many of the issues found with alternative affinity molecules, such as antibodies, and offer new, innovative solutions to bioprocessing, diagnostic and pharmaceutical scientists.

Aptamer Group has successfully delivered projects for global pharma companies, diagnostic development companies, and research institutes covering a range of targets and applications with the objective of establishing royalty-bearing licenses. Through the unique Optimer technology and processes, scientists and collaborators are enabled to make faster, more informed decisions that support discovery and development across the Life Sciences.

 

END

 

 

MSCEAFEFDFEAFAA